1
Back
Vaccine cover

Vaccine

IF3.5
Papers2140
Citations46558
Journal Papers 1903
Publication Date
delete
Immunoproteomics and reverse vaccinology identify a protective T-cell epitope from Fonsecaea pedrosoi for experimental chromoblastomycosis
deleteVaccine
IF3.5
delete2026-07-08
delete0
deleteOAAI
deleteIsabela de Godoy Menezes; Beatriz Viana Pereira; Renata Chaves Albuquerque; Sandro Rogerio de Almeida
deleteShare
deleteSave
Immunity gaps for several vaccine preventable diseases in Norway
deleteVaccine
IF3.5
delete2026-07-07
delete0
PREAI
deleteAudun Aase; Tove Karin Herstad; Margrethe Greve-Isdahl; Gro Tunheim
deleteShare
deleteSave
Australians' attitudes to mRNA vaccination in humans and animals: A cross-sectional survey
deleteVaccine
IF3.5
delete2026-07-07
delete0
deleteOAAI
deleteJane Williams; Chris Degeling; Laura Donovan; Kerrie Wiley
deleteShare
deleteSave
Barriers and facilitators to COVID-19 vaccination programme implementation in Ireland: a qualitative study of implementation stakeholders using CFIR
deleteVaccine
IF3.5
delete2026-07-06
delete0
deleteOAAI
deleteChikondi C. Kandulu; Aoife Fleming; Aoife O'Mahony; Sheena McHugh; Gillian W. Shorter; Emma Berry; Caoimhe Shields; Najam Sahar; Anne C. Moore; Laura J. Sahm
deleteShare
deleteSave
Retraction notice to “Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial” [Vaccine 82 (2026) 128588]
deleteVaccine
IF3.5
delete2026-07-06
delete0
PREAI
deleteLin Zhang; Tao Lin; Mengjie Wang; Xiaohui Ma; Huijuan Dong; Jintong Song; Yang Li
deleteShare
deleteSave
Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial
deleteVaccine
IF3.5
delete2026-07-03
delete0
deleteOAAI
deleteStéphanie Depickère; Pieter Pannus; Sarah Houben; Alexia Charles; Leo Heyndrickx; Daphnée Georges; Mathieu Verbrugghe; Arnaud Marchant; Isabelle Desombere; Kevin K. Ariën; Maria E. Goossens
deleteShare
deleteSave
Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study
deleteVaccine
IF3.5
delete2026-07-03
delete0
deleteOAAI
deleteTakashi Nakano; Satoshi Iwata; Kazunori Oishi; Eriko Iguchi; Yumi Suganuma; Yukio Tada; Shouta Saiki; Kumi Hashimoto; Hitomi Nakajima-Yoshida; Shinya Omoto; Tatsuya Yazaki; Takuhiro Sonoyama
deleteShare
deleteSave
A historical overview of the anti-vaccine movement and its public health implications
deleteVaccine
IF3.5
delete2026-07-02
delete0
PREAI
deleteJessica Brown; Haley Brennan; Carly Brand Levine; Lisa Gwynn
deleteShare
deleteSave
Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic
deleteVaccine
IF3.5
delete2026-07-02
delete0
PREAI
deleteNico Joel Halwe; Florian Krammer
deleteShare
deleteSave
Public health benefits of maternal influenza vaccination among pregnant women and infants <6 months in the United States, 2011–2020
deleteVaccine
IF3.5
delete2026-06-30
delete0
deleteOAAI
deleteSinead E. Morris; Alissa O'Halloran; Devi Sundaresan; Samantha M. Olson; Jessie R. Chung; Sascha Ellington; Catherine H. Bozio; A. Danielle Iuliano; Matthew Biggerstaff; Carrie Reed
deleteShare
deleteSave
V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023
deleteVaccine
IF3.5
delete2026-06-30
delete0
deleteOAAI
deleteTanya R. Myers; Lauren H. Zauche; Paige L. Marquez; Isaac McCullum; Anne M. Hause; David K. Shay
deleteShare
deleteSave
In silico selection and in vivo evaluation of scoloptoxin SSD14, Rm-inositol monophosphatase, and Rm-neprilysin as potential anti-tick vaccines
deleteVaccine
IF3.5
delete2026-06-30
delete0
deleteOAAI
deleteShafi Ullah; Luís Fernando Parizi; Mashal M. Almutairi; Abid Ali; Itabajara da Silva Vaz Junior
deleteShare
deleteSave
Effectiveness and acceptability of an opt-out nudge to promote influenza vaccination among medical residents: A randomized controlled trial
deleteVaccine
IF3.5
delete2026-06-30
delete0
PREAI
deleteAdriaan Barbaroux; Ilaria Serati; Isabelle Milhabet
deleteShare
deleteSave
Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies
deleteVaccine
IF3.5
delete2026-06-29
delete0
PREAI
deleteSolange Milolo Tshilumba; Paulina Morales Ruiz; Trésor Zola Matuvanga; Gwen Lemey; Primo Kimbulu; Mahmoud Abu Azoum; Maha Salloum; Gustave Kasereka; Felly Mitashi; Freddy Bikioli; Dominique Muteba; Aurelie Bisumba; Pierre Van Damme; Hypolite Muhindo-Mavoko; Elke Jordan; Jean-Pierre Van geertruyden; Vivi Maketa; Patrick Mitashi; Ynke Larivière
deleteShare
deleteSave
Human systemic and mucosal immune responses support further exploration of a Klebsiella pneumoniae protein-based vaccine
deleteVaccine
IF3.5
delete2026-06-29
delete0
deleteOAAI
deleteJoseph J. Campo; Oliver Pearse; Allan M. Zuza; Amit Oberai; Patricia Siyabu; Edith Tewesa; Luis Gadama; Samantha Lissauer; David Lissauer; Andy A. Teng; Jozelyn V. Pablo; Joshua M. Edgar; Adam D. Shandling; Kondwani Kawaza; Nicholas A. Feasey; Eva Heinz
deleteShare
deleteSave
Adverse events and vaccine administration errors following RSV vaccination: Findings from the United States VAERS database, 2023–2025
deleteVaccine
IF3.5
delete2026-06-29
delete0
deleteOAAI
deleteLotanna Ezeja; Oluchukwu M. Ezeala; Salisa C. Westrick; Jingjing Qian
deleteShare
deleteSave
Under-vaccination as a systems failure: A Monte Carlo simulation of the 2025 CDC/ACIP hepatitis B birth-dose policy shift and multi-level intervention packages, 2025–2035
deleteVaccine
IF3.5
delete2026-06-28
delete0
PREAI
deleteViraj Gandhi; Kush Kinariwala; G.L. Kesling
deleteShare
deleteSave
Corrigendum to “Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18–60 years: A double-blind, non-inferiority, randomized controlled trial” [Vaccine 42(9) (2024) 2254–2259]
deleteVaccine
IF3.5
delete2026-06-28
delete0
PREAI
deleteDavood Yadegarynia; Amirreza Keyvanfar; Hossein Keyvani; Shabnam Tehrani; Shahnaz Sali; Sara Abolghasemi
deleteShare
deleteSave
Innovative webinar-based training to support evidence-to-recommendation decision-making by national immunization technical advisory groups: multi-country experience with hexavalent vaccines
deleteVaccine
IF3.5
delete2026-06-28
delete0
deleteOAAI
deleteLisandro Torre; Stephen C. Hadler; Kathryn L. Hopkins; Theresa Sommers; Tyler Best; Sidy Ndiaye
deleteShare
deleteSave
Longitudinal changes in the antibody responses and adverse reactions across successive SARS-CoV-2 mRNA vaccinations from the primary series to the JN.1-adapted booster in hospital employees: A 4-year prospective cohort study
deleteVaccine
IF3.5
delete2026-06-26
delete0
deleteOAAI
deleteNaoki Tani; Tomonori Sato; Takeyuki Goto; Yukiko Harada; Takahiko Horiuchi; Koichi Akashi; Nobuyuki Shimono; Hideyuki Ikematsu; Yong Chong
deleteShare
deleteSave